Skip to main content

Table 1 Characteristics of the included studies

From: The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis

Reference

NOS

Country

Calendar period

Study type

Comparison population

Total no. of patients with IgG4-RD

Observed cancer cases

Expected cancer cases

Diagnostic criteria for IgG4-RD

Adjusted factors

Follow-up

Overall cancer SIR(95% CI)

Takahashi [6]

6

America

1986–2008

Registry-based

General America population

111

3.00

NA

HISORt criteria

Age, sex

331 person-years

16.0 (3.3–45.5)

Yamamoto et al. [8]

5

Japan

1997–2011

Registry-based

General Japan population

106

6.00

2.87

CDC

Age, sex

3.1 years

2.09 (0.77,4.55)

Shiokawa et al. [7]

7

Japan

2001–2011

Multicentre cohort

General Japan population

108

18.00

6.70

Asian diagnostic criteria [44], HISORt criteria

Age, sex, calendar year

3.3 years/415.7 person-years

2.70 (1.40,3.90)

Hirano et al. [3]

6

Japan

1997–2012

Multicentre cohort

General Japan population

113

15.00

NA

ICDC, CDC

Age, sex

6.1 years

1.04 (0.57,1.75)

Huggett et al. [9]

5

UK

2004–2013

Double-center cohort

General UK population

115

9.00

4.50

ICDC

Age, sex

2.7 years

2.00 (0.91,3.80)

Inoue et al. [10]

5

Japan

2005–2013

Registry-based

General Japan population

235

15.00

12.90

IgG4-RD Pathology Consensus Statement [45], ICDC

NA

3.1 years

1.16 (0.70,1.93)

Asano et al. [4]

6

Japan

1992–2012

Multicentre cohort

General Japan population

158

34.00

16.9

CDC, ICDC

Age, sex, calendar year

6.0 years/940 person-years

2.01 (1.34,2.69)

Sekiguchi et al. [12]

4

America

1994–2012

Registry-based

General America

population

166

9.0

NA

Modified CDC

NA

2.4 years

4.50 (1.50,7.50)

Ahn et al. [5]

6

Korea

2006–2015

Single-centre cohort

General Korea

population

118

5.0

0.52

CDC

NA

0.7 years

9.61 (3.12,22.40)

Tang et al. [13]

6

China

2011–2018

Single-centre cohort

General China

population

587

10.0

NA

CDC

Age, sex

5.1 years

2.78 (1.33,5.12)

  1. SIR standardized incidence ratio, CI confidence interval, NOS The Newcastle-Ottawa Scale, CDC Comprehensive Diagnostic Criteria for IgG4-RD [46], ICDC International Consensus Diagnostic Criteria for Autoimmune Pancreatitis [47], HISORt Criteria Diagnostic Criteria for Autoimmune Pancreatitis (Including Histology, Pancreatic imaging, Serology, Other organ involvement, Response to steroid therapy) [48], NA not available